Evidence map›Paper›PMID 24621502›Full record

ArticleCell cycle (Georgetown, Tex.)2014

Multi-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients.

Chunyan Li, Jingchao Bai, Xiaomeng Hao, Sheng Zhang, Yunhui Hu, Xiaobei Zhang, Weiping Yuan, Linping Hu, Tao Cheng, Anders Zetterberg and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Loss of FZO1 gene results in changes of cell dynamics in fission yeast.International journal of molecular medicine · 2020
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Chunyan LiKey Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
Jingchao BaiKey Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
Xiaomeng HaoKey Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
Sheng ZhangKey Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
Yunhui HuKey Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
Xiaobei ZhangKey Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
Weiping YuanBeijing Union Medical College Institute of Hematology and Blood Diseases Hospital; Chinese Academy of Medical Sciences; Tianjin, People's Republic of China.
Linping HuBeijing Union Medical College Institute of Hematology and Blood Diseases Hospital; Chinese Academy of Medical Sciences; Tianjin, People's Republic of China.
Tao ChengBeijing Union Medical College Institute of Hematology and Blood Diseases Hospital; Chinese Academy of Medical Sciences; Tianjin, People's Republic of China.
Anders ZetterbergClinical Pathology Department of the Karolinska Hospital; Karolinska Institute; Solna, Sweden.
Mong-Hong LeeDepartment of Molecular and Cellular Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA; Program in Cancer Biology; The University of Texas Graduate School of Biomedical Sciences at Houston; Houston, TX USA; Program in Genes and Development; The University of Texas Graduate School of Biomedical Sciences at Houston; Houston, TX USA.
J ZhangKey Laboratory of Breast Cancer Prevention and Therapy; Tianjin Medical University; Ministry of Education; Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Tianjin, People's Republic of China.
Tianjin People's Hospital · CNNational Clinical Research · USCentre for Cancer Biology · AUInstitute of Hematology & Blood Diseases Hospital · CNKarolinska Institutet · SETianjin Medical University Cancer Institute and Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a disease of cell cycle, and the dysfunction of cell cycle checkpoints plays a vital role in the occurrence and development of breast cancer. We employed multi-gene fluorescence in situ hybridization (M-FISH) to investigate gene copy number aberrations (CNAs) of 4 genes (Rb1, CHEK2, c-Myc, CCND1) that are involved in the regulation of cell cycle, in order to analyze the impact of gene aberrations on prognosis in the young breast cancer patients. Gene copy number aberrations of these 4 genes were more frequently observed in young breast cancer patients when compared with the older group. Further, these CNAs were more frequently seen in Luminal B type, Her2 overexpression, and tiple-negative breast cancer (TNBC) type in young breast cancer patients. The variations of CCND1, Rb1, and CHEK2 were significantly correlated with poor survival in the young breast cancer patient group, while the amplification of c-Myc was not obviously correlated with poor survival in young breast cancer patients. Thus, gene copy number aberrations (CNAs) of cell cycle-regulated genes can serve as an important tool for prognosis in young breast cancer patients.

Indexed as

Gene DosageGenes, cdcAdultAgedAge FactorsBreast NeoplasmsCheckpoint Kinase 2Cyclin D1Erb-b2 Receptor Tyrosine KinasesFemaleGenes, mycHumansIn Situ Hybridization, FluorescencePrognosisRetinoblastoma ProteinCCND1 protein, humanCheckpoint Kinase 2CHEK2 protein, humanCyclin D1ERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesRetinoblastoma Proteinbreast cancerCCND1CHEK2c-MycRb1survival analysis

Identifiers

PMID24621502
PMCPMC4049966
OpenAlexW1979321740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.